Tag: Cagrilintide

Business

Novo Nordisk Stock Plummets After FDA Delay for New Weight-Loss Drug

Thomas O'Reilly
Nov 24 2025
0 Comments

Novo Nordisk's stock plunged 18% after the FDA delayed approval of its next-gen weight-loss drug Cagrilintide, costing $28.7 billion in market value and raising questions about its future dominance in metabolic health.